| 
Peripheral natural killer cells are a prognostic factor in advanced oesogastric adenocarcinoma and are associated with intestinal types in the randomized trial PRODIGE17-ACCORD20 (UNICANCER GI).  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Honoraria - Amgen; Merck; Sanofi  | 
 | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
 | 
Consulting or Advisory Role - Merck Serono; Roche; Teva  | 
Speakers' Bureau - Amgen; Hospira; Lilly; Novartis  | 
Research Funding - Pierre Fabre  | 
|   | 
 | 
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche  | 
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
Christelle  De La Fouchardiere  | 
Consulting or Advisory Role - Bayer; Lilly; Roche  | 
 | 
Travel, Accommodations, Expenses - Celgene; Roche  | 
|   | 
 | 
Honoraria - Amgen; Lilly; Roche; Sanofi  | 
Consulting or Advisory Role - Amgen; Lilly; Roche; Sanofi  | 
Research Funding - Bayer (Inst)  | 
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; Roche  | 
|   | 
 | 
 | 
Honoraria - Bayer; Sanofi  | 
Consulting or Advisory Role - Amgen; Celgene; Lilly; Merck Serono; Roche  | 
Travel, Accommodations, Expenses - Celgene; Merck Serono  | 
|   | 
 | 
Consulting or Advisory Role - Bayer; Lilly; Roche  | 
 | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Honoraria - Amgen; Celgene; Lilly; Merck; Roche; Sanofi  | 
Travel, Accommodations, Expenses - Amgen; Merck; Roche  |